Procter & Gamble Health Ltd(PGHL)

NSE: PGHLBSE: 500126

₹ 5,027.3-0.78%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 8,345 crNext results: 2 Nov 2026Website: www.pghealthindia.comUpdated: 24 Oct 2026

About

Procter & Gamble Health Ltd, incorporated in 1967, manufactures and sells healthcare products, mainly vitamins, minerals and supplements under brands such as Neurobion and Evion. Its revenue was Rs 1407.97 Cr in FY26. Evion leads the Vitamin E category.^[1][2][3]

Products and brands

The company's main activity is the manufacture and sale of healthcare products, classified under NIC code 21002, as of FY25.^[1]
Evion leads the Vitamin E category. In FY25 the company gained share in Nerve Care, Vitamin E and Nasal Decongestant.^[3]
Products launched in FY26 include an easy-to-consume iron supplement, a nerve-pain relief product and a fatty liver solution, along with redesigned packaging.^[4]
Recent launches made up a high single-digit share of sales in FY25. Neurobion Alfa and Alfa D were growing at a high double-digit rate.^[3]

Key operating numbers

FY26 sales grew 16% over the matching 12-month period of the prior year. The company changed its fiscal year.^[4]
Productivity savings across ad spend, materials, manufacturing and overhead were INR 35 crore in FY26, compared with more than Rs 40 crore in FY25.^[4][3]
R&D spend was 386 lakhs (0.36% of turnover) in FY24, down from 571 lakhs in the prior year.^[5]

Market and category

The vitamins, minerals and supplements category grew at a 9% CAGR over the 3 years to FY26.^[4]
India's VMS category value grew 3.0% in the MAT to March 2025, mainly from pricing, with flat volume.^[3]

Customers and distribution

The company moved to a super-distributor go-to-market model, which it described in FY24 as a transformed model.^[5][3]
Neurobion's pharmacy reach grew 1.4x over the 5 years to FY25, adding nearly 100,000 stores.^[3]
In FY26 the company was expanding through e-pharmacies, e-commerce and quick commerce, and through distributor partnerships in white-space extra-urban markets.^[4]

Exports

Export revenue was about Rs 50 crore in the 9-month FY25, up 12%. The Sri Lanka business grew over 30%.^[3]

Recent developments

The company changed its fiscal year: FY25 was a 9-month period from July 2024 to March 2025.^[3][4]

Market Cap

₹8,345 Cr

High / Low

₹6,955 / 4,700

Stock P/E

23.4

Price / Book

15.9

Book Value

₹316

EPS

₹196.9

No. of Shares

1.66 Cr

ROCE

79.8%

ROE

61.6%

OPM

31.6%

Debt / Equity

0.00

Sales

₹1,408 Cr

Net Profit

₹327 Cr

Promoter holding

51.8%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials